JP4892335B2 - インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 - Google Patents

インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 Download PDF

Info

Publication number
JP4892335B2
JP4892335B2 JP2006502466A JP2006502466A JP4892335B2 JP 4892335 B2 JP4892335 B2 JP 4892335B2 JP 2006502466 A JP2006502466 A JP 2006502466A JP 2006502466 A JP2006502466 A JP 2006502466A JP 4892335 B2 JP4892335 B2 JP 4892335B2
Authority
JP
Japan
Prior art keywords
human
antibody
cells
antibodies
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006502466A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007528348A (ja
Inventor
デ ウィンケル， ヤン， ヘー．， イェイ． ファン
ダイク， マルクス， アントニーウス ファン
ジャニンヌ スヒュールマン，
アルナウト， エフ． ヒェリッツェン，
オレ， ディー．， エム．， エスシー バーズゴン，
ヨーン ペターセン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/374,932 external-priority patent/US7329405B2/en
Priority claimed from US10/379,741 external-priority patent/US7247304B2/en
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2007528348A publication Critical patent/JP2007528348A/ja
Application granted granted Critical
Publication of JP4892335B2 publication Critical patent/JP4892335B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006502466A 2003-02-26 2004-02-25 インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体 Expired - Lifetime JP4892335B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/374,932 2003-02-26
US10/374,932 US7329405B2 (en) 2001-08-23 2003-02-26 Human antibodies specific for interleukin 15 (IL-15)
US10/379,741 US7247304B2 (en) 2001-08-23 2003-03-05 Methods of treating using anti-IL-15 antibodies
US10/379,741 2003-03-05
PCT/IB2004/000484 WO2004076620A2 (en) 2003-02-26 2004-02-25 Human antibodies specific for interleukin 15 (il-15)

Publications (2)

Publication Number Publication Date
JP2007528348A JP2007528348A (ja) 2007-10-11
JP4892335B2 true JP4892335B2 (ja) 2012-03-07

Family

ID=36770634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502466A Expired - Lifetime JP4892335B2 (ja) 2003-02-26 2004-02-25 インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Country Status (6)

Country Link
JP (1) JP4892335B2 (ru)
CN (1) CN1780856A (ru)
AR (1) AR043405A1 (ru)
EA (1) EA015897B1 (ru)
RS (1) RS20050724A (ru)
ZA (1) ZA200506724B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2769984T (pt) 2007-05-11 2017-10-05 Altor Bioscience Corp Moléculas de fusão e variantes de il-15
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
PT2619229T (pt) 2010-09-21 2016-07-13 Altor Bioscience Corp Moléculas de fusão de il-15 multiméricas solúveis e métodos de produção e utilização das mesmas
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
KR20230028807A (ko) 2014-06-30 2023-03-02 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
JP2019521981A (ja) * 2016-06-15 2019-08-08 アムジエン・インコーポレーテツド セリアック病、非セリアックグルテン過敏症及び難治性セリアック病を治療するための方法及び組成物
AU2017345791B2 (en) 2016-10-21 2020-10-22 Altor Bioscience Corporation Multimeric IL-15-based molecules
PE20191497A1 (es) * 2016-12-21 2019-10-21 Cephalon Inc Anticuerpos que se unen especificamente a il-15 humana y usos de estos
CN114786479B (zh) * 2019-12-25 2023-12-15 江苏集萃药康生物科技股份有限公司 一种il-15人源化小鼠模型及其用途
CN114377133A (zh) * 2022-01-20 2022-04-22 山东大学 靶向肾脏cd8+trm形成与活化在肾小球损伤中的应用
CN115362984B (zh) * 2022-07-07 2024-01-16 成都中医药大学 一种小鼠自身免疫性甲状腺炎模型的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002003A1 (en) * 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
JP2002520294A (ja) * 1998-07-10 2002-07-09 ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー インターロイキン−１５拮抗薬によるセリアック病の治療
JP4359503B2 (ja) * 2001-08-23 2009-11-04 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520294A (ja) * 1998-07-10 2002-07-09 ザ マティルダ アンド テレンス ケネディ インスティチュート オブ リューマトロジー インターロイキン−１５拮抗薬によるセリアック病の治療
WO2001002003A1 (en) * 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
JP4359503B2 (ja) * 2001-08-23 2009-11-04 ゲンマブ エー／エス インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体

Also Published As

Publication number Publication date
JP2007528348A (ja) 2007-10-11
AR043405A1 (es) 2005-07-27
EA200501362A1 (ru) 2006-02-24
EA015897B1 (ru) 2011-12-30
RS20050724A (en) 2007-11-15
ZA200506724B (en) 2007-03-28
CN1780856A (zh) 2006-05-31

Similar Documents

Publication Publication Date Title
JP4359503B2 (ja) インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7247304B2 (en) Methods of treating using anti-IL-15 antibodies
AU2002332628A1 (en) Human antibodies specific for interleukin 15 (IL-15)
KR101329843B1 (ko) Ｃｄ25에 대한 인간 모노클로날 항체
JP4606172B2 (ja) 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
JP4999158B2 (ja) 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
CN103709250B (zh) 抗cd20的人单克隆抗体
JP4892335B2 (ja) インターロイキン１５（ｉｌ−１５）に特異的なヒト抗体
US7329405B2 (en) Human antibodies specific for interleukin 15 (IL-15)

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111219

R150 Certificate of patent or registration of utility model

Ref document number: 4892335

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141222

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term